Aptorum Group

NIKI · NASDAQ

$1.83−$0.03 (−1.61%)TodayMarket closed ·
Prev close $1.86

About NIKI

Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The firm's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.

Employees
1
Headquarters
London
Listed
Dec 18, 2018
Sector
Health Care
Industry
Biotechnology

Leadership

Aptorum Group executives
NameTitleSince
Ian Huen—2017
K.K. Wong——
Prof. Douglas Arner——
Prof. Justin Wu——

Similar companies

Companies in the same industry as Aptorum Group

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.